

CITATION REPORT

List of articles citing

A 4-year update on the safety of sildenafil citrate (Viagra)

**Harin Padma-nathan, Ian Eardley, Robert A Kloner,
Alan M Laties, Francesco Montorsi**

**DOI: 10.1016/s0090-4295(02)01752-1
Urology, 2002, 60, 67-90.**

Source: <https://exaly.com/paper-pdf/34202298/citation-report.pdf>

Version: 2022-05-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
183	Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. <i>Current Urology Reports</i> , 2003 , 4, 457-65	2.8	70
182	Erectile dysfunction in the cardiac patient. <i>Current Urology Reports</i> , 2003 , 4, 466-71	2.8	16
181	Sildenafil: A 4-year update in the treatment of 20 million erectile dysfunction patients. <i>Current Urology Reports</i> , 2003 , 4, 488-96	2.8	31
180	What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. <i>International Journal of Impotence Research</i> , 2003 , 15, 412-7	2	24
179	Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate. <i>International Journal of Impotence Research</i> , 2003 , 15, 444-9	2	20
178	Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. <i>International Journal of Impotence Research</i> , 2003 , 15 Suppl 5, S13-9	2	16
177	Erectile dysfunction in the cardiac patient: how common and should we treat?. <i>Journal of Urology</i> , 2003 , 170, S46-50; discussion S50	0.4	162
176	Sildenafil in erectile dysfunction: a critical review. <i>Current Medical Research and Opinion</i> , 2003 , 19, 241-62.3		85
175	Genetic Risk Factors for Erectile Dysfunction and Genetic Determinants of Drug Response [On the Way to Improve Drug Safety?]. <i>Herz</i> , 2003 , 28, 304-13	2.4	13
174	Sildenafil citrate does not affect cardiac contractility in human or dog heart. <i>Current Medical Research and Opinion</i> , 2003 , 19, 747-52	2.3	65
173	Heart Disease and Erectile Dysfunction. , 2004 , ,		
172	Treatment of invasive bladder cancer: lessons from the past and perspective for the future. <i>Japanese Journal of Clinical Oncology</i> , 2004 , 34, 295-306	2.5	21
171	Sex, lies, and Niagra. <i>Journal of the American Medical Association</i> , 2004 , 291, 560-2	21.1	10
170	Treatment of erectile dysfunction. <i>International Journal of STD & AIDS</i> , 2004 , 15, 215-21	1.3	7
169	Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. <i>Andrologia</i> , 2004 , 36, 106-10	2.2	26
168	A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. <i>International Journal of Impotence Research</i> , 2004 , 16, 2-7	2	34
167	Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales. <i>International Journal of Impotence Research</i> , 2004 , 16, 527-30	2	13

166	Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. <i>British Journal of Cancer</i> , 2004 , 90, 578-81	8.1	28
165	Duration of action of sildenafil citrate in men with erectile dysfunction. <i>The Journal of Sexual Medicine</i> , 2004 , 1, 179-84	0.9	41
164	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. <i>American Journal of Cardiology</i> , 2004 , 93, 147-53	2.9	83
163	Assessment of cardiovascular risk in patients with erectile dysfunction. <i>Endocrine</i> , 2004 , 23, 125-9		14
162	Psychotherapy for erectile dysfunction. <i>Endocrine</i> , 2004 , 23, 131-4		35
161	Novel phosphodiesterase type 5 inhibitors: Assessing hemodynamic effects and safety parameters. <i>Clinical Cardiology</i> , 2004 , 27, 120-5	3	25
160	Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: Comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. <i>Current Urology Reports</i> , 2004 , 5, 467-71	2.8	41
159	Erectile dysfunction in the cardiac patient. <i>Comprehensive Therapy</i> , 2004 , 30, 50-4		6
158	Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis. <i>EAU Update Series</i> , 2004 , ,		
157	Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 68S-72S	4.4	113
156	The discovery and development of Viagra [®] (sildenafil citrate). , 2004 , , 1-13		7
155	Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis. <i>EAU Update Series</i> , 2004 , 2, 56-63		17
154	Male sexuality with advancing age. <i>European Journal of Obstetrics Gynecology and Reproductive Biology</i> , 2004 , 113, 123-5	1.5	28
153	Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. <i>Urology</i> , 2004 , 63, 762-7		66
152	Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. <i>Journal of Clinical Hypertension</i> , 2004 , 17, 139-45	2.1	54
151	Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression. <i>International Clinical Psychopharmacology</i> , 2004 , 19, 191-9	1.9	33
150	Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. <i>Annals of Internal Medicine</i> , 2004 , 141, 169-77	6.8	225
149	Drugs acting on the cerebral and peripheral circulations. <i>Side Effects of Drugs Annual</i> , 2004 , , 209-212	0.1	

148	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 459-68	3.7	18
147	Erectile dysfunction in patients with coronary artery disease. <i>International Journal of Impotence Research</i> , 2005 , 17, 209-15	2	21
146	Characteristics of sildenafil erections in healthy young men. <i>Asian Journal of Andrology</i> , 2005 , 7, 395-8	2.6	6
145	Sildenafil Non-Responders: Haemodynamic and Morphometric Studies. <i>European Urology</i> , 2005 , 48, 136-9; discussion 139	9.6	44
144	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. <i>American Journal of Cardiology</i> , 2005 , 95, 36-42	2.9	54
143	Sexual activity and cardiac risk. <i>American Journal of Cardiology</i> , 2005 , 96, 24M-28M	2.9	31
142	Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>The Journal of Sexual Medicine</i> , 2005 , 2, 848-55	0.9	32
141	Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. <i>The Journal of Sexual Medicine</i> , 2005 , 2, 415-25; discussion 425-7	0.9	87
140	Brachytherapy in the treatment of invasive bladder cancer. <i>Seminars in Radiation Oncology</i> , 2005 , 15, 49-54	5	10
139	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. <i>World Journal of Urology</i> , 2005 , 23, 374-84	3.7	27
138	Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. <i>Journal of Managed Care Pharmacy</i> , 2005 , 11, 674-80		9
137	Clinical monograph for drug formulary review: erectile dysfunction agents. <i>Journal of Managed Care Pharmacy</i> , 2005 , 11, 151-71		19
136	Effect of sildenafil citrate on the cardiovascular system. <i>Brazilian Journal of Medical and Biological Research</i> , 2005 , 38, 1303-11	2.7	8
135	Erectile Dysfunction: Anatomical Parameters, Etiology, Diagnosis, and Therapy. <i>Archives of Andrology</i> , 2005 , 51, 15-31		25
134	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. <i>Expert Opinion on Drug Metabolism & Toxicology</i> , 2005 , 1, 283-93	4.9	33
133	Sildenafil Citrate, the Classic PDE5 Inhibitor. , 2005 , , 65-83		4
132	The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. <i>Urologic Clinics of North America</i> , 2005 , 32, 217-30, vii	2.4	8
131	Oral Pharmacotherapy for Male Sexual Dysfunction. , 2005 , ,		

130	Recreational Use and Misuse of Phosphodiesterase 5 Inhibitors. <i>Journal of the American Pharmacists Association</i> , 2005 , 45, 63-75	2.9	54
129	A Comparative Review of the Options for Treatment of Erectile Dysfunction. <i>Drugs</i> , 2005 , 65, 1621-50	11.1	136
128	Aging in the Hypothalamic-Pituitary-Testicular Axis. , 2006 , , 2697-2728		5
127	Club Drugs as Causal Risk Factors for HIV Acquisition Among Men Who Have Sex with Men: A Review. <i>Substance Use and Misuse</i> , 2006 , 41, 1551-601	2	166
126	The Role of Erection Hardness in Determining Erectile Dysfunction (ED) Treatment Outcome. <i>European Urology Supplements</i> , 2006 , 5, 767-772	0.1	5
125	Partner Satisfaction and Successful Treatment Outcomes for Men with Erectile Dysfunction (ED). <i>European Urology Supplements</i> , 2006 , 5, 779-785	0.1	8
124	Oral Therapy for Erectile Dysfunction. , , 271-286		
123	Pattern of Sildenafil Calls to Texas Poison Control Centers, 1998-2004. <i>Journal of Toxicology and Environmental Health</i> , 2006 , 69, 497-503	3.1	1
122	Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. <i>Urology</i> , 2006 , 68, 47-60	2	56
121	Erectile Dysfunction in the Patients with Cardiovascular Disease. <i>Korean Journal of Urology</i> , 2006 , 47, 279		3
120	., 2006 , ,		
119	Oral Pharmacotherapy of Erectile Dysfunction. , , 75-93		5
118	Management of sildenafil treatment failures. <i>Current Opinion in Urology</i> , 2006 , 16, 449-59	2.5	34
117	Abnormal vascular tone in infants and children with lung hypoplasia: Findings from cardiac catheterization and the response to chronic therapy. <i>Pediatric Critical Care Medicine</i> , 2006 , 7, 589-94	2.9	44
116	Successful use of surfactant to treat severe intrapulmonary hemorrhage after iatrogenic lung injury--A case report. <i>Pediatric Critical Care Medicine</i> , 2006 , 7, 583-5	2.9	10
115	Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. <i>Journal of Applied Physiology</i> , 2006 , 100, 2031-40	3.4	104
114	Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. <i>International Journal of Clinical Practice</i> , 2006 , 60, 500-3	2.7	52
113	Self-esteem, confidence, and relationships in men treated with sildenafil citrate for erectile dysfunction. <i>Journal of General Internal Medicine</i> , 2006 , 21, 1069-74	4	33

112	Outcome analysis of sildenafil citrate for erectile dysfunction of Japanese patients. <i>International Journal of Impotence Research</i> , 2006 , 18, 302-5	2	6
111	Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness. <i>International Journal of Impotence Research</i> , 2006 , 18, 423-31	2	25
110	Preference studies are of value to the field of sexual medicine: Con. <i>Current Sexual Health Reports</i> , 2006 , 3, 9-12	1.2	
109	Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. <i>The Journal of Sexual Medicine</i> , 2006 , 3, 12-27	0.9	62
108	Comparison between sildenafil-treated subjects with erectile dysfunction and control subjects on the Self-Esteem And Relationship questionnaire. <i>The Journal of Sexual Medicine</i> , 2006 , 3, 274-82	0.9	41
107	Positive Effect of Counseling and Dose Adjustment in Patients with Erectile Dysfunction who Failed Treatment with Sildenafil. <i>European Urology</i> , 2006 , 50, 134-40	9.6	60
106	Update on Phosphodiesterase (PDE) Isoenzymes as Pharmacologic Targets in Urology: Present and Future. <i>European Urology</i> , 2006 , 50, 1194-207; discussion 1207	9.6	79
105	Pharmacology of erectile dysfunction in man. , 2006 , 111, 400-23		47
104	Sildenafil in the treatment of erectile dysfunction. <i>Aging Health</i> , 2007 , 3, 295-303		3
103	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <i>International Journal of Impotence Research</i> , 2007 , 19, 281-95	2	33
102	How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. <i>International Journal of Urology</i> , 2007 , 14, 339-42; discussion 343	2.2	24
101	Phosphodiesterase Type 5 Inhibitors: The Day After. <i>European Urology</i> , 2007 , 51, 75-88; discussion 89	9.6	77
100	trans-resveratrol relaxes the corpus cavernosum ex vivo and enhances testosterone levels and sperm quality in vivo. <i>Archives of Pharmacal Research</i> , 2008 , 31, 83-7	5.6	47
99	Cardiovascular outcomes among sildenafil users: results of the International Men's Health Study. <i>International Journal of Clinical Practice</i> , 2008 , 62, 367-73	2.7	12
98	JSSM Guidelines for erectile dysfunction. <i>International Journal of Urology</i> , 2008 , 15, 564-76	2.2	9
97	Analysis of single items on the Self-Esteem And Relationship questionnaire in men treated with sildenafil citrate for erectile dysfunction: results of two double-blind, placebo-controlled trials. <i>BJU International</i> , 2008 , 101, 861-6	5.2	13
96	British Society for Sexual Medicine guidelines on the management of erectile dysfunction. <i>The Journal of Sexual Medicine</i> , 2008 , 5, 1841-65	0.9	102
95	Relationship factors in the development and maintenance of ED: implications for treatment effectiveness. <i>The Journal of Sexual Medicine</i> , 2008 , 5, 1795-804	0.9	23

94	Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. <i>The Journal of Sexual Medicine</i> , 2008 , 5, 2170-8	0.9	107
93	Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension. <i>The Journal of Heart and Lung Transplantation</i> , 2008 , 27, 1326-32	0.9	18
92	Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. <i>Urology</i> , 2008 , 72, 613-6	2	65
91	Integrating evidence from multiple sources to evaluate post-approval safety: an example of sildenafil citrate and cardiovascular events. <i>Current Medical Research and Opinion</i> , 2008 , 24, 1861-8	2.3	9
90	The prognostic significance of pathologic stage T0 on organ-confined bladder transitional cell carcinoma following radical cystectomy. <i>Urologia Internationalis</i> , 2008 , 81, 394-8	1.6	7
89	Self-esteem, confidence and relationship satisfaction in men with erectile dysfunction: a randomized, parallel-group, double-blind, placebo-controlled study of sildenafil in Mexico. <i>International Journal of Impotence Research</i> , 2008 , 20, 402-8	2	9
88	Phosphodiesterase Type-5 Inhibitor and Oxidative Stress. <i>International Journal of Immunopathology and Pharmacology</i> , 2008 , 21, 879-89	2.9	31
87	Fermentation filtrates of <i>Rubus coreanus</i> relax the corpus cavernosum and increase sperm count and motility. <i>Journal of Medicinal Food</i> , 2008 , 11, 474-8	2.6	9
86	External beam radiotherapy for the treatment of muscle invasive bladder cancer. , , , 106-124		
85	Attrition From an Internet-Based Psychological Intervention for Erectile Dysfunction: Who is Likely to Drop Out?. <i>Journal of Sex & Marital Therapy</i> , 2009 , 35, 391-401	2.5	9
84	The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2009 , 55, 815-25	9.6	280
83	Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. <i>International Journal of Clinical Practice</i> , 2010 , 64, 240-55	2.7	116
82	Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 511-7	0.8	58
81	Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3486-95	2.9	20
80	Phosphodiesterase type 5 inhibitors: unmet needs. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3476-85	2.9	29
79	Bladder cancer. <i>Current Opinion in Oncology</i> , 2009 , 21, 272-7	3.8	43
78	Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. <i>Clinical Therapeutics</i> , 2010 , 32, 1178-87	3.1	53
77	Standards for clinical trials in male sexual dysfunctions. <i>The Journal of Sexual Medicine</i> , 2010 , 7, 414-44	0.9	35

76	Pharmacotherapy for erectile dysfunction. <i>The Journal of Sexual Medicine</i> , 2010 , 7, 524-40	0.9	134
75	Handbook of Evidence-Based Radiation Oncology. , 2010 , ,		34
74	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1427-37	5.5	57
73	Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. <i>Urology</i> , 2010 , 75, 387-91	2	86
72	Sex Therapy: Advances in Paradigms, Nomenclature, and Treatment. <i>Academic Psychiatry</i> , 2010 , 34, 390-6.3		8
71	Newer Phosphodiesterase Inhibitors: Comparison with Established Agents. <i>Urologic Clinics of North America</i> , 2011 , 38, 155-63	2.4	11
70	Contemporary Treatment of Erectile Dysfunction. , 2011 , ,		2
69	Role of Radiation Therapy for the Treatment of Lymph Nodes in Urologic Malignancies. <i>Urologic Clinics of North America</i> , 2011 , 38, 497-506, vii	2.4	1
68	Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. <i>BJU International</i> , 2011 , 107, 1605-10	5.2	13
67	Bladder preservation by concurrent chemoradiation for muscle-invasive bladder cancer: Applicability in low-income countries. <i>Reports of Practical Oncology and Radiotherapy: Journal of Great Poland Cancer Center in Poznań and Polish Society of Radiation Oncology</i> , 2011 , 16, 178-83	1.4	4
66	Intensity modulated radiotherapy for elderly bladder cancer patients. <i>Radiation Oncology</i> , 2011 , 6, 75	4.1	24
65	Optimizing postoperative sexual function after radical prostatectomy. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 347-65	3.1	11
64	Why stop a good thing? Discontinuing PDE5 inhibitors. <i>Nature Reviews Urology</i> , 2012 , 9, 483-5	5.1	
63	Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i> , 2012 , 125, 1058-72	5.1	213
62	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i> , 2012 , 126, e354-471	5.1	469
61	<i>Journal of the American College of Cardiology</i> , 2012 , 60, e44-e164	4.4	1229
60	A Randomized, Open-Label, 3-Way Crossover Study to Demonstrate Bioequivalence of Sildenafil Powder for Oral Suspension With Tablets Used Commercially and in Clinical Studies for the Treatment of Pulmonary Arterial Hypertension. <i>Clinical Pharmacology in Drug Development</i> , 2012 , 1, 152-7	2.1	1
59	Selective bladder preservation with curative intent for muscle-invasive bladder cancer: A contemporary review. <i>International Journal of Urology</i> , 2012 , 19, 388-401	2.2	51

58	Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. <i>The Journal of Sexual Medicine</i> , 2012 , 9, 857-65	0.9	24
57	Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012 , 56, 18-30	1.6	15
56	Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. <i>BJU International</i> , 2012 , 110, 1801-6	5.2	38
55	Does patient age affect survival after radical cystectomy?. <i>BJU International</i> , 2012 , 110, E486-93	5.2	22
54	SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>The Journal of Sexual Medicine</i> , 2013 , 10, 130-71	0.9	122
53	Discordance between preoperative and postoperative bladder cancer location: implications for partial-bladder radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 85, 707-13	0.8	6
52	Exploring the association between erectile rigidity and treatment adherence with sildenafil. <i>The Journal of Sexual Medicine</i> , 2013 , 10, 1861-6	0.9	5
51	Bladder cancer. <i>Journal of the National Comprehensive Cancer Network</i> , 2013 , 11, 446-75	5.8	276
50	CEFALALGIA INDUZIDA PELA TADALAFILA - RELATO DE CASO E REVISÃO DA LITERATURA. <i>Revista Médica Da UFPR</i> , 2014 , 1, 109		
49	Stiff fingers as an unwanted side effect of intravascular tadalafil gel abuse. <i>Annals of the Royal College of Surgeons of England</i> , 2014 , 96, e19-20	2	1
48	Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy. <i>PLOS ONE</i> , 2014 , 9, e91327	3.4	27
47	Avanafil for male erectile dysfunction: a systematic review and meta-analysis. <i>Asian Journal of Andrology</i> , 2014 , 16, 472-7	2.6	8
46	Trimodality bladder-sparing approach versus radical cystectomy for invasive bladder cancer. <i>Journal of Radiotherapy in Practice</i> , 2014 , 13, 428-437	1.2	6
45	Cardiovascular outcomes among sildenafil users: results of the International Men's Health Study: M.A. Mittleman, M. Maclure, M.A. Lewis, G.C. Hall, N. Moore, F. Giuliano, H. Porst, H. Hedelin, A. Martin-Morales, R.E. Sobel, R. Reynolds, and D.B. Glasser. <i>The Journal of Sexual Medicine</i> , 2014 , 11, 880-884	0.9	
44	Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. <i>Radiation Oncology</i> , 2014 , 9, 213	4.1	13
43	Comparison of the simplified International Index of Erectile Function (IIEF-5) in patients of erectile dysfunction with different pathophysiologies. <i>BMC Urology</i> , 2014 , 14, 52	2.1	23
42	Sexual Activity and Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2014 , 16, 445	3.9	15
41	Trimodality Therapy in Bladder Cancer: Who, What, and When?. <i>Urologic Clinics of North America</i> , 2015 , 42, 169-80, vii	2.4	22

40	Management of Bladder Cancer. , 2015 , ,			1
39	Drug therapy for erectile dysfunction. , 2016 , , 172-193			
38	Diagnostik und medikamentöse Therapie der erektilen Dysfunktion. , 2016 , , 1513-1521			
37	Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016 , 8, 249-256	3.1		7
36	An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e67-74	3		2
35	. <i>European Urology</i> , 2017 , 71, 952-960	9.6		159
34	The Magic Pill: The Branding of Impotence and the Positioning of Viagra as Its Solution through Edutainment. <i>Journal of Health Communication</i> , 2018 , 23, 281-290	2.4		3
33	Sexual activity and cardiovascular disease, erectile dysfunction as a predictor of ischemic heart disease. <i>Cor Et Vasa</i> , 2018 , 60, e296-e305	0.3		
32	Trimodal therapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 1219-1229	3.3		1294
31	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network</i> , 2018 , 16, 1041-1053	5.8		123
30	The Surveillance for Muscle-Invasive Bladder Cancer (MIBC). , 2018 , , 553-597			
29	Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market. <i>Sexual Medicine Reviews</i> , 2018 , 6, 583-594	5.2		12
28	Bladder preservation therapy in muscle-invasive bladder cancer: Current evidence and future perspectives. <i>AME Medical Journal</i> , 2020 , 5, 16-16	0.9		1
27	Sudden headache due to perimesencephalic subarachnoid hemorrhage after self-medication with 200 mg sildenafil: Case report and discussion. <i>Clinical Neurology and Neurosurgery</i> , 2020 , 194, 105844	1.8		1
26	Sildenafil in ophthalmology: An update. <i>Survey of Ophthalmology</i> , 2021 , ,	5.6		1
25	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. , 2004 , , 139-161			1
24	Erectile Dysfunction: Pharmacological Therapy. , 2011 , , 675-696			1
23	Phosphodiesterase 5. , 2006 , ,			8

- 22 Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. *Clinical Interventions in Aging*, **2006**, 1, 403-14 3-7 32
- 21 Sexualität mit 60?. , **2003**, , 20-24
- 20 Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction. , **2004**, , 35-47
- 19 Treating Psychogenic Erectile Dysfunction. , **2004**, , 235-240
- 18 The phosphodiesterase V inhibitor low responder study (PILRS) in patients with erectile dysfunction – A rationale for a PDE5 inhibitor combination therapy. , **2004**, , 169-181
- 17 Sexual Activity As a Trigger of Myocardial Infarction/Ischemia. , **2004**, , 251-260
- 16 NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. , **2004**, , 163-168
- 15 Risk of Heart Attack After Sexual Activity. , **2004**, , 279-288
- 14 The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors. , **2004**, , 131-137
- 13 Sildenafil, pharmacology of a highly selective PDE5 inhibitor. , **2004**, , 15-33 2
- 12 Middle adulthood: ages 40–4. , **2004**, , 92-113
- 11 Andrologie. *Fortschritte Der Praktischen Dermatologie Und Venerologie*, **2005**, , 599-602
- 10 Prevention of Vasculogenic Erectile Dysfunction in Rat Model by the Chronic Administration of Oral Rho Kinase Inhibitor. *Korean Journal of Urology*, **2006**, 47, 322
- 9 Erectile Dysfunction and Cardiovascular Disease. , **2007**, , 2791-2801
- 8 Vardenafil: a biochemically potent phosphodiesterase type 5 inhibitor. , **2008**, , 268-276
- 7 DRUGS THAT ACT ON THE CEREBRAL AND PERIPHERAL ARTERIAL AND VENOUS CIRCULATIONS. , **2009**, , 431-448
- 6 Oral Therapy for Erectile Dysfunction. , **2011**, , 93-106 11
- 5 Recent Status of the Treatment of Erectile Dysfunction. *Journal of the Nihon University Medical Association*, **2013**, 72, 142-145 0

4 Phosphodiesterase-5 Inhibitors in Cardioprotection. , **2013** , , 439-458

3 Diagnostik und medikamentöse Therapie der erektilen Dysfunktion. , **2014** , , 1-12

2 Phosphodiesterase type V inhibitors. , **2016** , , 734-742

1 Adoption of green methodology in industry for the synthesis of Sildenafil citrate & Celecoxib: A case study. *Materials Today: Proceedings*, **2022** , ,

1.1